header
Image from OpenLibrary

The effect of sofosbuvir on cryoglobulinemic vsculitis / Mohamed Tharwat Ebrahim Mohamed Hegazy ; Supervised Gaafar Mohamed Ragab , Sherif Faruk Elkhamisy , Luca Quartuccio

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Mohamed Tharwat Ebrahim Mohamed Hegazy , 2017Description: 149 P. : facsimiles ; 25cmOther title:
  • تأثير عقار سوفوسبيوفير علي الالتهاب الوعائي المرتبط بالكريوجلوبيولينات [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Internal Medicine Summary: Cryoglobulinemic Vasculitis (CV) is a systemic vasculitis affecting small and medium-sized vessels. CV is triggered by hepatitis C virus (HCV). Sofosbuvir (Sovaldi), an NS5B polymerase inhibitor, is one of the Direct Acting Antivirals (DAAs), used for the treatment of chronic HCV.Objectives: Assess the effect of Sofosbuvir on Cryoglobulinemic Vasculitis. Methods: Our study included 34 HCV-CV patients fulfilling the newly validated international classification criteria and were treated by one of the approved protocols by the national committee for treatment of Hepatitis C virus in Egypt. Our patients were assessed regarding: Clinical manifestations, disease activity and laboratory investigations. Results: All patients showed a sustained viral response (SVR). Clinical manifestations significantly improved at the end of treatment (EOT) including constitutional manifestations (85.3%), skin purpura (100%), arthralgia (76.5%) and peripheral neuropathy (67.6.5%). Serum levels of cryocrit, rheumatoid factor and complement 4 significantly improved at EOT (85.2%, 82.3% and 73.5%; P value <0.001, <0.001 and 0.005 respectively). There is a statistical significant improvement in Birmingham Vasculitis activity score 3 (BVAS 3) with p-value <0.001. After 12 months from the start of antiviral therapy, in 23 patients, regardless the treatment protocol, articular and constitutional manifestations as well as cryocrit response showed significant deterioration (P value: 0.009, 0.006 and 0.002 respectively) despite sustained viral response after 24 weeks (SVR 24). There was a statistical significant over-expression of B cell-activating factor (BAFF) and A proliferation-inducing ligand (APRIL). There was also over-expression of DNA breaks and DNA repair genes at EOT
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.18.Ph.D.2017.Mo.E (Browse shelf(Opens below)) Not for loan 01010110074664000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.18.Ph.D.2017.Mo.E (Browse shelf(Opens below)) 74664.CD Not for loan 01020110074664000

Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Internal Medicine

Cryoglobulinemic Vasculitis (CV) is a systemic vasculitis affecting small and medium-sized vessels. CV is triggered by hepatitis C virus (HCV). Sofosbuvir (Sovaldi), an NS5B polymerase inhibitor, is one of the Direct Acting Antivirals (DAAs), used for the treatment of chronic HCV.Objectives: Assess the effect of Sofosbuvir on Cryoglobulinemic Vasculitis. Methods: Our study included 34 HCV-CV patients fulfilling the newly validated international classification criteria and were treated by one of the approved protocols by the national committee for treatment of Hepatitis C virus in Egypt. Our patients were assessed regarding: Clinical manifestations, disease activity and laboratory investigations. Results: All patients showed a sustained viral response (SVR). Clinical manifestations significantly improved at the end of treatment (EOT) including constitutional manifestations (85.3%), skin purpura (100%), arthralgia (76.5%) and peripheral neuropathy (67.6.5%). Serum levels of cryocrit, rheumatoid factor and complement 4 significantly improved at EOT (85.2%, 82.3% and 73.5%; P value <0.001, <0.001 and 0.005 respectively). There is a statistical significant improvement in Birmingham Vasculitis activity score 3 (BVAS 3) with p-value <0.001. After 12 months from the start of antiviral therapy, in 23 patients, regardless the treatment protocol, articular and constitutional manifestations as well as cryocrit response showed significant deterioration (P value: 0.009, 0.006 and 0.002 respectively) despite sustained viral response after 24 weeks (SVR 24). There was a statistical significant over-expression of B cell-activating factor (BAFF) and A proliferation-inducing ligand (APRIL). There was also over-expression of DNA breaks and DNA repair genes at EOT

Issued also as CD

There are no comments on this title.

to post a comment.